肝细胞癌的循证管理:2002-2020年随机对照试验的系统综述与Meta分析
该研究系统综述了2002至2020年间肝细胞癌各疾病分期的III期随机对照试验,最终纳入49项高质量试验共22113例患者。Meta分析显示,免疫检查点抑制剂治疗在病毒性肝炎相关肝细胞癌中疗效显著优于非病毒性病因,而酪氨酸激酶抑制剂/抗血管生成治疗未显示病因相关差异。
要点
- 49项高质量III期RCT中仅9项阳性,6种治疗被指南采纳。
- 免疫治疗在病毒性肝炎相关HCC中疗效更优,TKI/抗VEGF无病因差异。
核心结论
- 2002至2020年间49项高质量III期RCT中9项获得阳性结果,免疫治疗可能对病毒性病因肝细胞癌更有效。
研究设计与样本
- 系统综述2002至2020年各疾病分期的III期随机对照试验,从10100项研究中筛选出76项III期RCT,经严格算法识别49项高质量试验,共22113例患者,涵盖辅助治疗7项、早期2项、中期7项、晚期一线21项及二线12项。
主要发现
- 49项高质量试验中9项阳性,6种治疗被指南采纳:索拉非尼(2项RCT)、仑伐替尼、阿替利珠单抗联合贝伐珠单抗、瑞戈非尼、卡博替尼和雷莫芦单抗。
- 2种治疗未被指南采纳:辅助CIK细胞治疗和索拉非尼联合肝动脉灌注FOLFOX。
- 纳入8项试验共3739例患者的Meta分析显示,免疫检查点抑制剂治疗在病毒性肝炎相关HCC中疗效显著优于非病毒相关HCC,而TKI/抗VEGF治疗未观察到病因相关疗效差异。
临床怎么用
- 对于病毒性肝炎相关肝细胞癌患者,免疫检查点抑制剂治疗可能带来更优疗效。
- TKI/抗VEGF治疗的疗效未显示与病因相关,选择时无需依据病毒学病因分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous randomized controlled trials (RCTs) have aimed at improving outcomes across disease stages. We aimed to analyze the current evidence and identify potential factors influencing response to therapies. METHODS: We conducted a systematic review of phase III RCTs (2002-2020) across disease stages. A meta-analysis was designed to examine the relationship between etiology and outcome after systemic therapies with either tyrosine-kinase inhibitor (TKI)/antiangiogenic or immune checkpoint inhibitor (ICI) therapy. RESULTS: Out of 10,100 studies identified, 76 were phase III RCTs. Among them, a rigorous screening algorithm identified 49 with high quality including a total of 22,113 patients undergoing adjuvant (n = 7) and primary treatment for early (n = 2), intermediate (n = 7), and advanced (first-line, n = 21; second-line, n = 12) stages of disease. Nine of these trials were positive, 6 treatments have been adopted in guidelines (sorafenib [2 RCTs], lenvatinib, atezolizumab+bevacizumab, regorafenib, cabozantinib and ramucirumab), but 2 were not (adjuvant CIK cells and sorafenib plus hepatic arterial infusion with FOLFOX). Meta-analysis of 8 trials including 3739 patients revealed ICI therapy to be significantly more effective in patients with viral hepatitis compared with nonviral-related HCC, whereas no differences related to etiology were observed in patients treated with TKI/anti-vascular endothelial growth factor. CONCLUSIONS: Among 49 high-quality RCTs conducted in HCC during 2002-2020, 9 resulted in positive results. A meta-analysis of systemic therapies suggests that immunotherapies may be more effective in viral etiologies.
引用
- Haber PK, Puigvehí M, Castet F, et al. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). Gastroenterology. 2021. PMID: 34126063. doi:10.1053/j.gastro.2021.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。